Determining a Tolerable Dose of Primaquine in G6PD-deficient Persons Without Malaria in Mali (PQSAFETY)
Sponsor: Bill and Melinda Gates Foundation
Listed as NCT02535767, this PHASE1/PHASE2 trial focuses on Malaria and remains completed. Sponsored by Bill and Melinda Gates Foundation, it has been updated 7 times since 2015, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Mar 2022 — Jul 2024 [monthly]
Completed PHASE1_PHASE2
-
Jan 2021 — Mar 2022 [monthly]
Completed PHASE1_PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE1_PHASE2
▶ Show 2 earlier versions
-
Feb 2017 — Jun 2018 [monthly]
Completed PHASE1_PHASE2
Phase: PHASE2 → PHASE1_PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE2
First recorded
Aug 2015
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Bill and Melinda Gates Foundation
- Malaria Research and Training Center, Bamako, Mali
- Radboud University Medical Center
- University of California, San Francisco
- University of Mississippi Medical Center
For direct contact, visit the study record on ClinicalTrials.gov .